Submission is based on results from the pivotal REACH3 study
New approval will see Libtayo compete with blockbuster immunotherapy Keytruda
The no-fault compensation fund will be accessible via a web portal by 31 March 2021
Company announced clinical hold on gene therapy earlier this month after suspected serious adverse reaction